Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Trial status:Recruitment Complete
Trial ID:
BNT142-01
NCT ID:
NCT05262530
EudraCT ID:
2021-005481-18
EU Trial (CTIS) Number:
2024-512639-58-00
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruitment Complete

Trial Details

This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.

Medical Condition
  • Solid Tumors
    • Trial Drug
  • BNT142
    • Phase
    Phase 1/Phase 2
    Type
    Interventional
    Estimated Enrolment
    73
    Estimated Trial Date
    Mar 2022 - Dec 2025

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    University of Maryland Medical Center
    Baltimore, Maryland, United States, 21201
    Status
    Location
    Duke University Medical Center
    Durham, North Carolina, United States, 27705
    Status
    Location
    University of Pennsylvania
    Philadelphia, Pennsylvania, United States, 19104
    Status
    Location
    The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States, 77030
    Status
    Location
    South Texas Accelerated Research Therapeutics (START) - San Antonio
    San Antonio, Texas, United States, 78229
    Status
    Location
    NEXT Virginia
    Fairfax, Virginia, United States, 22031
    Status
    Go to page